P&G Hygiene FY26: PAT up 19%, dividend ₹255/share

Management update and why it matters

Procter & Gamble Hygiene and Health Care Ltd (P&G Hygiene) used its latest analyst and investor interaction to outline how it managed profitability expansion in FY26 even as sales stayed broadly flat. For the year ended March 31, 2026, management indicated sales of about ₹4,300 crore, largely unchanged versus the comparable period. Profit after tax (PAT), however, was reported at about ₹850 crore and described as up 19% year-on-year. The company also shared that it continued to invest back into the business during the year. For investors, the key takeaway is the combination of steady revenue, stronger bottom line, and continued spending on innovation and go-to-market.

Analyst and institutional investor meet on June 18

P&G Hygiene has scheduled a virtual connect meeting with analysts and institutional investors for June 18, 2026, at 2:30 p.m. IST. The company’s leadership participation referenced in the provided material included V. Kumar, managing director, and Vidya Shankar, incoming chief financial officer. The stated agenda of the presentation is focused on performance, results, strategy, and business outlook. Such interactions typically help the market understand what is driving margins and what operational priorities management is funding. In this case, the company explicitly linked FY26 actions to targeted investments and an integrated growth strategy.

FY26 audited numbers: multiple disclosures, consistent direction

P&G Hygiene disclosed audited financial results for FY26 with an unmodified audit opinion from statutory auditors. In separate references within the provided text, FY26 sales were cited as ₹4,300 crore (management commentary), ₹4,290 crore (audited result summary), and revenue from operations of ₹4,281.59 crore (₹428,159 lakh). Similarly, PAT was cited as about ₹850 crore in management remarks and ₹857 crore in the audited result summary, while net profit for FY26 was also listed as ₹860.79 crore (₹86,079 lakh). Across these data points, the direction is consistent: revenue was broadly flat while profits rose meaningfully. The company also reported earnings per share (EPS) of ₹263.86 for FY26.

Profit growth despite flat sales

The material attributes FY26 performance to targeted investments alongside continued focus on innovation and strengthening the go-to-market. Management said these steps are expected to support “sustained balanced growth” and long-term competitiveness in the categories it plays in. While the text does not provide a detailed cost breakdown for P&G Hygiene, it does provide a quantified productivity lever. The company reported productivity savings of ₹86 crore in FY26. For investors, productivity savings matter because they can help fund brand and distribution investments without compressing margins.

Category highlight: Whisper Period Panties

In the analyst/investor meet summary included in the provided content, P&G Hygiene highlighted strong performance in Whisper Period Panties, stating that the business tripled. The note is important because it indicates specific sub-category momentum even when overall sales are flat. It also provides context for management’s emphasis on innovation and go-to-market strengthening. However, the text does not provide an absolute revenue figure for this product line, so its contribution cannot be quantified here. Still, the mention signals where the company believes it is seeing outsized traction.

Dividend announcements and timelines

P&G Hygiene declared a total dividend of ₹255 per share for the fiscal year, as stated in the audited results summary. Separately, the board recommended a final dividend of ₹60 per equity share, subject to shareholder approval at the AGM. The company said the dividend, if approved, will be paid on or before September 18, 2026. Dividend-related disclosures are closely tracked because they reflect board confidence and capital allocation policy. The provided information does not specify the split between interim and final dividend beyond the final ₹60 per share recommendation.

Separate market update: Procter & Gamble Health Ltd jumps after Q4

A separate set of figures in the provided text relates to Procter & Gamble Health Limited (PGHL), which moved sharply after quarterly results. PGHL’s stock was reported up 12.17% to ₹6,339.65 after it announced Q4 FY26 earnings. For Q4 FY26, standalone net profit was stated at ₹94.60 crore, up 54.63% year-on-year and 21.92% quarter-on-quarter. Revenue from operations rose 19.12% year-on-year to ₹370.45 crore, though it was down 0.91% sequentially from ₹373.86 crore in Q3 FY26. Profit before tax (PBT) was reported at ₹133.21 crore for the quarter.

Cost and cash flow indicators from PGHL’s FY26 disclosures

The PGHL update also included cost line items for Q4 FY26: total expenditure of ₹234.86 crore, raw material costs of ₹85.19 crore, and employee expenses of ₹50.86 crore. For the full year ended March 31, 2026, net sales were reported at ₹1,407.97 crore and PAT at ₹326.91 crore, with PBT at ₹449.86 crore. Net cash from operating activities was reported at ₹337.79 crore in FY26 versus ₹168.69 crore in FY25. The board recommended a final dividend of ₹45 per equity share (face value ₹10) for FY26, as per the text.

Key figures at a glance

What investors will watch next

For P&G Hygiene, the June 18, 2026 virtual connect is the next scheduled event mentioned, and it is expected to focus on strategy, performance, and business outlook. Investors are likely to track whether productivity savings continue at similar levels, and whether innovation-led categories translate into broader revenue traction beyond flat sales. Dividend approvals at the AGM and the payment timeline up to September 18, 2026 are also clear milestones from the company’s disclosure. For PGHL, the market’s immediate response highlights sensitivity to quarterly earnings momentum and cash generation figures reported for FY26. Any further updates would need to be read alongside subsequent filings and management commentary.